Single Spheroid Metabolomics

Sample preparation for metabolomics analysis always involves transferring samples to ice after compound or metabolite treatment. This affects the metabolic profile. To overcome this drawback, we can enable automated workflows using the Pu·MA System 3D. 

You perform drug treatments during the course of an assay without disturbing the spheroid and subsequently add in the lysing solution at a specified time point to lyse the spheroid in situ before analysing the lysed samples by mass spec analysis.

The tabs below showcase this application of in situ lysis for metabolomics using the  Pu·MA System.

Spheroid Control vs Treated

Use of Pu·MA System 3D for Single Spheroid Assays with Downstream Metabolomics

single spheroid metabolomics data

This application note demonstrates the use of the Pu·MA System for spheroid treatment with drugs followed by in situ lysis for preparing samples for downstream metabolomics analysis.

 

Automated Long-Term 3D Cell-Based Toxicity Studies Using a Flowchip System

We presented data about how you can single spheroid drug treatment and dosing. The spheroid samples were lysed within the incubator and samples analyzed for metabolic changes. 

 

Metabolomics Prep Workflow

Organoids, media and reagents are loaded into the flowchips. The Pu·MA System performs the automated steps described below in the workflow.

 

 

 

 

 

 

 

If you have questions about using the Pu·MA System for applications with your samples, please reach out via the Contact Us page or you can Request a Quote.

Contact Us

Protein Fluidics, Inc.

875 Cowan Road, Suite B,
Burlingame, CA 94010

+1 650 529 5080

info@proteinfluidics.com

#pumasystem  #flowchip  #3dcellassay

Our Company

For Research Use Only. Not for diagnostic use. Protein Fluidics, Protein Fluidics Logo and Pu·MA System are registered trademarks of Protein Fluidics, Inc. in the United States and internationally. All other trademarks belong to their respective owners. All rights reserved. © 2024 PROTEIN FLUIDICS, INC.